Key facts
- Grannus Therapeutics’s last known valuation is $5.0M (Jan 2022).
- It has raised $2.9M across 2 recorded rounds; the latest was Seed Round ($950K) in Jan 2022.
- Notable investors include Plug and Play Tech Center, Elevate Ventures, 1842 Fund, Economic Development Corporation, National Cancer Institute — 7 tracked in total.
- Grannus Therapeutics has filed 2 Form Ds with the SEC since 2022, most recently Jan 2024 ($800K sold to 9 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Grannus Therapeutics
Funding rounds
2 roundsAbout Grannus Therapeutics
Operator of a pre-clinical stage biotechnology company intended to support a cancer treatment. The company develops a molecule that selectively inhibits specific isoforms of Hsp90, addresses the toxicity and dosing challenges that pan-inhibitors experienced in oncology clinical trials, and expands the therapeutic potential of the Hsp90 target to other therapeutic areas, enabling healthcare professionals to treat multiple types of cancers
- Sector
- Healthcare
- HQ
- Indianapolis, IN, United States
- Founded
- 2020
- Employees
- 2
- Website
- grannustherapeutics.com/
- Ownership
- Privately Held (backing)
Grannus Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Grannus Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Grannus Therapeutics in its N-PORT filings yet. We sweep new filings monthly.